Telix and UniQuest to Collaborate on Radiolabelled Immune Targeting Peptide
![]() |
MELBOURNE, Australia, Oct. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a collaboration with UniQuest Pty Ltd (UniQuest), the commercialisation company of The University of Queensland (UQ), to develop a radiolabelled molecule targeting an immune checkpoint protein. The announcement was...
Read more: Telix and UniQuest to Collaborate on Radiolabelled Immune Targeting Peptide





